Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives $37.64 Average PT from Analysts

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the eleven analysts that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and ten have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $37.64.

Several research analysts have weighed in on SNDX shares. Bank of America lifted their target price on Syndax Pharmaceuticals from $30.00 to $31.00 and gave the company a "buy" rating in a research note on Thursday, August 15th. Stifel Nicolaus lifted their target price on Syndax Pharmaceuticals from $40.00 to $41.00 and gave the company a "buy" rating in a research note on Monday, October 14th. The Goldman Sachs Group lifted their target price on Syndax Pharmaceuticals from $30.00 to $33.00 and gave the company a "buy" rating in a research note on Thursday, November 7th. Barclays lifted their target price on Syndax Pharmaceuticals from $32.00 to $33.00 and gave the company an "overweight" rating in a research note on Thursday, August 15th. Finally, UBS Group started coverage on Syndax Pharmaceuticals in a research note on Thursday, October 24th. They issued a "buy" rating and a $37.00 target price on the stock.

Syndax Pharmaceuticals Trading Down 0.5 %

SNDX traded down $0.08 during trading on Tuesday, hitting $16.62. 804,736 shares of the stock were exchanged, compared to its average volume of 2,399,961. Syndax Pharmaceuticals has a 1-year low of $15.00 and a 1-year high of $25.34. The stock has a fifty day moving average price of $18.41 and a two-hundred day moving average price of $19.76.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.98) EPS for the quarter, topping the consensus estimate of ($1.13) by $0.15. The firm had revenue of $12.50 million for the quarter, compared to analyst estimates of $9.16 million. During the same period last year, the firm earned ($0.73) EPS. On average, research analysts predict that Syndax Pharmaceuticals will post -2.39 EPS for the current year.

Hedge Funds Weigh In On Syndax Pharmaceuticals

A number of institutional investors have recently made changes to their positions in SNDX. CANADA LIFE ASSURANCE Co raised its holdings in shares of Syndax Pharmaceuticals by 28.4% in the first quarter. CANADA LIFE ASSURANCE Co now owns 7,182 shares of the company's stock worth $171,000 after acquiring an additional 1,587 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in Syndax Pharmaceuticals by 69.5% in the first quarter. Price T Rowe Associates Inc. MD now owns 44,510 shares of the company's stock valued at $1,060,000 after purchasing an additional 18,243 shares during the last quarter. Janus Henderson Group PLC increased its stake in Syndax Pharmaceuticals by 85.1% in the first quarter. Janus Henderson Group PLC now owns 48,948 shares of the company's stock valued at $1,164,000 after purchasing an additional 22,501 shares during the last quarter. California State Teachers Retirement System increased its stake in Syndax Pharmaceuticals by 1.5% in the first quarter. California State Teachers Retirement System now owns 76,557 shares of the company's stock valued at $1,822,000 after purchasing an additional 1,150 shares during the last quarter. Finally, DNB Asset Management AS increased its stake in Syndax Pharmaceuticals by 40.6% in the second quarter. DNB Asset Management AS now owns 13,172 shares of the company's stock valued at $270,000 after purchasing an additional 3,804 shares during the last quarter.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).